Collectively, our results demonstrate that PD-1 blockade induces tumor-specific IgG1<sup>+</sup> plasma cell responses that complement cellular immunity and contribute to clinical benefit, underscoring a coordinated humoral-cellular axis in effective antitumor immunity. This evidence concerns the gene PDCD1 and neoplasm.